What Investors Should Know About Medpace CEO Troendle Selling $10 Million in Stock
Troendle retains a $3.27 billion combined stake, representing 19% of the market cap, with the majority of holdings controlled through Medpace Investors, LLC.
Overview
August J. Troendle, President & CEO of Medpace Holdings, Inc. (NASDAQ:MEDP), sold 15,978 shares of common stock in a transaction valued at $10.0 million. SEC Form 4 filing
Transaction value based on SEC Form 4 weighted average sale price ($623.93); post-transaction value based on Aug. 24, 2026, market close ($620.03).
Details
Medpace Holdings operates as a leading independent contract research organization with a global footprint, leveraging its 6,500-person workforce and established infrastructure to deliver integrated clinical development services. The company has demonstrated strong financial performance with TTM revenue of $2.8 billion and net income of $491.5 million, reflecting robust demand for outsourced clinical research capabilities. Medpace's competitive positioning is reinforced by its comprehensive service offerings, operational scale, and established relationships with pharmaceutical and biotechnology clients across multiple therapeutic areas.
Source
Originally published at www.fool.com.
Related Articles
- I’m 56 with $1.4 million and want to retire in 5 years. Do I move to California, New York or overseas?
- Wall Street’s massive bet against long-term bonds is a recipe for a painful bearish unwind, says Citadel Securities
- 2 Artificial Intelligence (AI) Stocks That Can Skyrocket Up to 484%, According to Select Wall Street Analysts